Learn More About the PROSERA Study
Now enrolling: The PROSERA phase 3 study of seralutinib in adults with pulmonary arterial hypertension.
Evidence of Target Engagement and Modulation: Biomarker Analysis of the Phase 1b Inhaled Seralutinib Study
